Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia.
Department of Immunology and Pathology, Monash University, Melbourne, VIC, Australia.
Front Immunol. 2018 Nov 9;9:2572. doi: 10.3389/fimmu.2018.02572. eCollection 2018.
Tumor necrosis factor-alpha (TNF) is a pleiotropic cytokine, which is thought to play a major role in the pathogenesis of inflammatory diseases, including allergy. TNF is produced at the early stage of allergen sensitization, and then continues to promote the inflammation cascade in the effector phase of allergic reactions. Consequently, anti-TNF treatment has been proposed as a potential therapeutic option. However, recent studies reveal anti-intuitive effects of TNF in the activation and proliferative expansion of immunosuppressive Tregs, tolerogenic DCs and MDSCs. This immunosuppressive effect of TNF is mediated by TNFR2, which is preferentially expressed by immunosuppressive cells. These findings redefine the role of TNF in allergic reaction, and suggest that targeting TNF-TNFR2 interaction itself may represent a novel strategy in the treatment of allergy.
肿瘤坏死因子-α(TNF)是一种多效细胞因子,被认为在包括过敏在内的炎症性疾病的发病机制中起主要作用。TNF 在过敏原致敏的早期阶段产生,然后继续促进过敏反应效应阶段的炎症级联反应。因此,抗 TNF 治疗被提议作为一种潜在的治疗选择。然而,最近的研究揭示了 TNF 在免疫抑制性 Tregs、耐受性 DC 和 MDSCs 的激活和增殖扩张中的反直觉作用。TNF 的这种免疫抑制作用是由 TNFR2 介导的,TNFR2 优先在免疫抑制性细胞上表达。这些发现重新定义了 TNF 在过敏反应中的作用,并表明靶向 TNF-TNFR2 相互作用本身可能代表治疗过敏的一种新策略。